{"id":"NCT00488631","sponsor":"Janssen Research & Development, LLC","briefTitle":"An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis","officialTitle":"A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2011-10","completion":"2015-02","firstPosted":"2007-06-20","resultsPosted":"2013-11-11","lastUpdate":"2016-04-26"},"enrollment":1228,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Colitis, Ulcerative"],"interventions":[{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Golimumab 50 mg","otherNames":[]},{"type":"BIOLOGICAL","name":"Golimumab 100 mg","otherNames":[]},{"type":"BIOLOGICAL","name":"Golimumab 200 mg","otherNames":[]}],"arms":[{"label":"Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance","type":"PLACEBO_COMPARATOR"},{"label":"GLM-I-Rsp-Golimumab 50 mg Maintenance","type":"EXPERIMENTAL"},{"label":"GLM-I-Rsp-Golimumab 100 mg Maintenance","type":"EXPERIMENTAL"},{"label":"Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance","type":"PLACEBO_COMPARATOR"},{"label":"PBO-I-nonRsp-Golimumab 100 mg Maintenance","type":"EXPERIMENTAL"},{"label":"GLM-I-nonRsp-Golimumab 100 mg Maintenance","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and efficacy of golimumab administered subcutaneously (under the skin) injections in maintenance therapy.","primaryOutcome":{"measure":"Number of Participants in Clinical Response Through Week 54","timeFrame":"Induction Baseline, Week 0 through Week 54","effectByArm":[{"arm":"Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance","deltaMin":48,"sd":null},{"arm":"GLM-I-Rsp-Golimumab 50 mg Maintenance","deltaMin":71,"sd":null},{"arm":"GLM-I-Rsp-Golimumab 100 mg Maintenance","deltaMin":75,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.010"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":297,"countries":["United States","Australia","Austria","Belgium","Bulgaria","Canada","Czechia","Denmark","France","Germany","Hungary","India","Israel","Japan","Latvia","Lithuania","Netherlands","New Zealand","Poland","Romania","Russia","Serbia","Slovakia","South Africa","Sweden","Ukraine"]},"refs":{"pmids":["37691729","35154389","31982148","30847474","29917070","23770005"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":156},"commonTop":["Colitis Ulcerative","Nasopharyngitis","Headache","Upper Respiratory Tract Infection","Arthralgia"]}}